Targeting metabolic pathways to combat Epstein-Barr virus infections
The Epstein-Barr virus can cause a spectrum of diseases, including a range of cancers. Emerging data now show that inhibition ...
Tag: Lymphoma
Proteins in the blood could warn people of cancer more than seven years before it is diagnosed
In a recent study published in Nature Communications, researchers from the United Kingdom (UK) investigated associations between 1,463 plasma proteins ...
Heart transplant recipient's journey: From patient to advocate
Glen Kelley's journey as a heart transplant recipient came full circle today in Prague, as he addressed attendees of the ...
Scientists discover a key mechanism used by human herpesvirus 8 to induce cancer
Cleveland Clinic researchers have discovered a key mechanism used by Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 ...
Spatial profiling predicts recurrence of Hodgkin lymphoma after bone marrow transplant
Cedars-Sinai Cancer investigators have discovered a new way to predict whether a cancer of the immune system will recur in ...
Brazilian review explores emerging therapies for advanced Hodgkin lymphoma
A new review paper was published in Oncotarget's Volume 14 on December 12, 2023, entitled, "Current perspectives on the management ...
New combination treatment offers hope for older patients with mantle cell lymphoma
The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients ...
MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer
AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) ...
Experimental antibody treatment shows promise for preventing bone marrow transplant complication
An experimental antibody treatment largely prevented a bone marrow transplant complication called graft versus host disease (GVHD) in the intestines, ...
Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-cel
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen ...